Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cyclacel Pharmaceuti
(NQ:
CYCC
)
1.270
-0.050 (-3.79%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cyclacel Pharmaceuti
< Previous
1
2
3
4
5
6
Next >
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
June 20, 2023
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.
Via
Benzinga
Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
June 20, 2023
Gainers
Via
Benzinga
Recap: Cyclacel Pharmaceuticals Q1 Earnings
May 11, 2023
Via
Benzinga
Oppenheimer Maintains Outperform Rating for Cyclacel Pharmaceuticals: Here's What You Need To Know
March 07, 2023
Via
Benzinga
A Preview Of Cyclacel Pharmaceuticals's Earnings
March 03, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 20, 2023
It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Tuesday morning!
Via
InvestorPlace
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
May 11, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Release First Quarter 2023 Financial Results
May 04, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Announces Receipt of $4.7 Million R&D Tax Credit
May 03, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Participate in March Investor Conferences
March 07, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Reports Fourth Quarter And Full Year 2022 Financial Results And Provides Business Update
March 06, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023
From
Cyclacel
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
February 16, 2023
Via
Benzinga
Cyclacel Pharmaceuticals to Participate in the 2023 BIO CEO & Investor Conference
January 30, 2023
From
Cyclacel
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
January 17, 2023
Via
Benzinga
Cyclacel Pharmaceuticals Reviews 2022 Achievements and Announces Key Business Objectives for 2023
January 05, 2023
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals to Present at Biotech Showcase and Participate in a Corporate Access Event During the J.P. Morgan Healthcare Conference in January 2023
December 15, 2022
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022
From
Cyclacel
Via
GlobeNewswire
Earnings Outlook For Cyclacel Pharmaceuticals
November 08, 2022
Cyclacel Pharmaceuticals (NASDAQ:CYCC) is set to give its latest quarterly earnings report on Wednesday, 2022-11-09. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Cyclacel Pharmaceuticals to Release Third Quarter 2022 Financial Results
November 03, 2022
From
Cyclacel
Via
GlobeNewswire
Cyclacel Reports Preliminary Data From Its Phase 1/2 Clinical Trial of Oral Fadraciclib in Patients With Solid Tumors and Lymphoma at ENA 2022
October 26, 2022
Daily dosing of fadraciclib was well tolerated; single agent activity observed across multiple tumor types including 2 PRs in T-cell lymphoma patients
From
Cyclacel
Via
GlobeNewswire
Cyclacel Hosting Research & Development Day
October 24, 2022
From
Cyclacel
Via
GlobeNewswire
Cyclacel Pharmaceuticals To Present Preliminary Data From The Phase 1/2 Clinical Trial Of Oral Fadraciclib At The 34th EORTC-NCI-AACR Symposium
October 13, 2022
- Preliminary Dose Escalation Data to be Presented on Novel CDK2/9 Inhibitor Fadraciclib in Patients with Solid Tumors and Lymphoma -
From
Cyclacel
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
August 17, 2022
We've got the news behind the biggest pre-market stock movers for Wednesday morning that traders need to know about this morning!
Via
InvestorPlace
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
August 19, 2022
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 11, 2022
Via
Benzinga
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
August 18, 2022
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66.
Via
Benzinga
Why Is Disney Higher By More Than 7%: Here Are 40 Stocks Moving Premarket
August 11, 2022
Gainers
Via
Benzinga
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
August 12, 2022
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results.
Via
Benzinga
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session
August 11, 2022
Gainers Timber Pharmaceuticals, Inc. (NYSE: TMBR) shares rose 63.8% to $0.1769. Timber Pharmaceuticals recently announced closing of $8.0 million public offering.
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.